A module novel for detecting and addressing patients at high risk of lung cancer laureate in the call for projectss ” Third Iplaces of experimentation » of the national digital health strategy France 2030
Historically known for its scientific database to help prescribe and dispense medication, Claude BernardRESIP (Band Cegedim) throw a news platform designed to better meet the needs of healthcare professionals. Based on Artificial Intelligenceshe integrated the database Claude Bernard as well as many others scientific services that allowsent to create links between the various health actors and the information systems. His ambition ? Propose tools innovative for hassure better patient careespecially in the case of illnesss severes can be detecteds upstream.
For nearly a year, the R&D department of Claude Bernard has been heavily involved in the development of this new technological platform. Thanks to its dual medical and technical expertise, the portal Claude Bernard was organized around 4 pillars the prediction ; the diagnosis ; addressing and improving the patient journey; the Monitoring.
Designed to be interfaced with all business software used on the market, the platform Claude Bernard allows healthcare professionals to benefit from the latest digital advances in their practice management software. Decision support programs (therapeutic and clinical) are hosted there and APIs will allow them to be distributed on any business software (office management software, pharmacy, hospital, diary, teleconsultation …). Supported directly by the platform, the development of new scientific services also avoids software publishers having to make additional investments in specific developments.
the 1er Medical Intelligence module of the platform Claude Bernard developed in collaboration with Gustave Roussy retained in the call for projectss ” Third Iplaces of experimentation » of the national digital health strategy France 2030
Beyond the initial webservices of Claude Bernard such as prescription and dosage control, monograph display, to secure drug management and fight against iatrogenics, users can now benefit from a new module for detecting and addressing patients at high risk of lung cancer.
This module was developed for the program Interception led by Gustave Roussy, one of the winners of an experimental project in the Third Places Interception, himself a winner of Ia first wave of‘Call for projects “Third places of experimentation” of the national digital health strategy France 2030launched by the government.
“Cegedim’s advanced medical technology, via the Claude Bernard digital services platform, and strong penetration in the community medicine market, result in an innovative organizational solution. A rich collaboration in the service of lung cancer prevention within the framework of Gustave Roussy’s Interception program”, indicates Suzette Delaloge Director of the Interception Program of Gustave Roussy.
“We are very proud of this technological innovation which offers great prospects for health prevention. Tomorrow, the platform will integrate new risk calculation programs and algorithms for other types of cancers and diseases,” says Arnault Billy, SVP Strategic Development of Cegedim.
The content of the Claude Bernard database must be considered as a scientific work that is the subject of critical consultation, leaving to health professionals the responsibilities of prescription, dispensing or administration, in particular that the health code recognizes. . RESIP cannot guarantee the accuracy and completeness of the information contained in the Claude Bernard database. Indeed, although the data and functionalities of the Claude Bernard database are developed with extreme vigilance, the user must be informed that due to the complexity of this database on medicines and health products, RESIP declines any liability for any consequences that may result from an error in prescription, delivery, administration or more generally in the use of the Claude Bernard database. As a result, RESIP cannot be held responsible for the consequences resulting from the use of the Claude Bernard database.
About the Claude Bernard platform and scientific base:
Subsidiary of the Cegedim Group, RESIP (Research and Studies in Professional Computer Systems) provides health professionals with the scientific database to help prescribe and dispense Claude Bernard drugs (formerly BCB). Already HAS approved and CE marked medical device, Claude Bernard is integrated into the business software used by more than 150,000 health professionals in pharmacies, medical practices, multidisciplinary health centers and care establishments: hospitals, clinics and nursing homes…
More than 300,000 drugs and marketed health products are referenced there and are updated daily. For more information : https://www.bcb.fr/
Claude Bernard is also a digital platform that integrates other scientific services to create links with the various health actors to ensure better patient care.
Founded in 1969, Cegedim is an innovative technology and services group specializing in the management of digital flows in the healthcare and BtoB ecosystem, as well as in the design of business software for healthcare and insurance professionals. Cegedim has more than 5,600 employees in more than 10 countries and achieved a turnover of 525 million euros in 2021.
Cegedim SA is listed on the Paris Stock Exchange (EURONEXT: CGM).
To know more : www.cegedim.fr
And follow Cegedim on Twitter: @CegedimGroup, LinkedIn and Facebook
Such. : +33 (0)6 52 08 13 66
We wish to give thanks to the writer of this short article for this remarkable web content
Claude Bernard: an innovative platform dedicated to medical intelligence and new scientific services to support healthcare professionals
Take a look at our social media accounts along with other related pageshttps://www.ai-magazine.com/related-pages/